<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>65</volume><submitter>Labroy M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Photodynamic diagnosis (PDD) is widely used in bladder cancer management, enabling fluorescence-guided detection of lesions through intravesical administration of photosensitizers such as hexaminolevulinate (Cysview®/Hexvix®). Building on this clinical framework, we explored photodynamic therapy (PDT) using pheophorbide a (pheo), a chlorophyll-based photosensitizer, encapsulated in self-assembled poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO&lt;sub>5000&lt;/sub>-PCL&lt;sub>4000&lt;/sub>) micelles.&lt;h4>Results&lt;/h4>In vitro assays were performed on human bladder cancer cell lines, namely the grade 3 invasive T24 and the grade 1 SW780, in both 2D monolayers and 3D spheroid cultures. In 2D, encapsulated pheo showed higher phototoxicity (IC₅₀: 129 nM T24, 156 nM SW780), while free </pubmed_abstract><journal>Translational oncology</journal><pagination>102687</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12903199</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.</pubmed_title><pmcid>PMC12903199</pmcid><pubmed_authors>Fourquaux I</pubmed_authors><pubmed_authors>Gibot L</pubmed_authors><pubmed_authors>Bolduc S</pubmed_authors><pubmed_authors>Bordeleau F</pubmed_authors><pubmed_authors>Chabaud S</pubmed_authors><pubmed_authors>Labroy M</pubmed_authors><pubmed_authors>Durand M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.</name><description>&lt;h4>Background&lt;/h4>Photodynamic diagnosis (PDD) is widely used in bladder cancer management, enabling fluorescence-guided detection of lesions through intravesical administration of photosensitizers such as hexaminolevulinate (Cysview®/Hexvix®). Building on this clinical framework, we explored photodynamic therapy (PDT) using pheophorbide a (pheo), a chlorophyll-based photosensitizer, encapsulated in self-assembled poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO&lt;sub>5000&lt;/sub>-PCL&lt;sub>4000&lt;/sub>) micelles.&lt;h4>Results&lt;/h4>In vitro assays were performed on human bladder cancer cell lines, namely the grade 3 invasive T24 and the grade 1 SW780, in both 2D monolayers and 3D spheroid cultures. In 2D, encapsulated pheo showed higher phototoxicity (IC₅₀: 129 nM T24, 156 nM SW780), while free </description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-07-06T03:14:33.156Z</modification><creation>2026-07-06T03:10:47.087Z</creation></dates><accession>S-EPMC12903199</accession><cross_references><pubmed>41650805</pubmed><doi>10.1016/j.tranon.2026.102687</doi></cross_references></HashMap>